Abrilada
Product Images NDC 0025-0319

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Abrilada (NDC 0025-0319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Abrilada 01)

A line graph comparing the percent of ACR20 responders over time (weeks) between two groups: one receiving 40 mg every other week and a placebo group. The graph shows the percent responders on the y-axis (0 to 70%) and time in weeks on the x-axis (0 to 48). The treatment group shows a higher percentage of responders throughout the duration compared to placebo.*

FDA Label Image

Figure 2 (Abrilada 02)

A line graph displaying % ASAS 20 Response over time (weeks) comparing ADALIMUMAB (N=208) with Placebo (N=107). The y-axis shows response percentage from 0 to 70%, and the x-axis shows time from 0 to 26 weeks. ADALIMUMAB response increases steeply initially, peaking around 60%, then slightly decreases but remains higher than Placebo throughout the study duration.*

FDA Label Image

Study Uv I (Abrilada 02a)

A line graph depicting treatment failure rates over time in months for three groups: placebo, adalimumab, and another treatment, with the x-axis representing time in months and the y-axis representing treatment failure rate percentage. The graph includes numerical data points below the x-axis for each group at various times.*

FDA Label Image

Study Uv Ii (Abrilada 02b)

A line graph showing treatment failure rate (%) over time (months) for three groups: Treatment, Placebo, and Adalimumab. The x-axis represents time in months from 0 to 20, and the y-axis represents the treatment failure rate percentage from 0% to 100%. The graph compares the effectiveness of treatments over the observed period.*

FDA Label Image

Pfizer (Abrilada 03)

FDA Label Image

Pfizer (Abrilada 04)

FDA Label Image

Step 3 (Abrilada 05)

An instructional illustration labeled Step 3 shows a person holding a device and checking the medicine and expiration date through a small window. The image emphasizes verifying the medication details on the device, relevant to the ABRILADA product.*

FDA Label Image

Image (Abrilada 06)

An instructional diagram showing the components of the ABRILADA injection pen. The labeled parts include the cap, a window, an injection button, and an expiration date visible on the pen's label near the injection button.*

FDA Label Image

Step 4 (Abrilada 07)

An instructional diagram titled 'Step 4 Choose and prepare the injection site' showing a front view of a human torso and upper legs. It highlights recommended injection areas: the abdomen, at least 2 inches (5 cm) away from the belly button, and the front upper thigh.*

FDA Label Image

Step 5 (Abrilada 08)

An instructional illustration labeled Step 5 showing a hand removing the cap from an injectable pen device by pulling it straight off, indicated by a red arrow pointing away from the device.*

FDA Label Image

C:\temp\pfizer Oct 4\attached File _1664891496641_2578536_2022_09_20_81a33cfa-262f_11027\abrilada-09.jpg (Abrilada 09)

An instructional diagram labeled Step 6 showing how to insert the needle by pushing it down. The image uses arrows to indicate the needle being pressed and inserted into a vial or injection site, with a hand holding the syringe vertically.*

FDA Label Image

Step 7 (Abrilada 10)

An instructional illustration showing step 7 for injecting medicine using an auto-injector device. It demonstrates pressing the device down until a click sound, holding it in place with an inset showing a second click, and then holding for 5 more seconds before releasing. The steps are organized in three columns labeled Press, Keep holding, and Wait.*

FDA Label Image

Step 8 (Abrilada 11)

Illustration labeled Step 8 showing a hand holding a syringe with a visible window displaying a red indicator. The image highlights checking the window area on the syringe, likely as part of an instructional sequence for medication administration.*

FDA Label Image

Step 9 (Abrilada 12)

Instructional illustration from ABRILADA showing Step 9 of the injection process. It depicts a hand firmly gripping the injection device while an upward red arrow indicates removing the pen from the injection site, with the caption 'Remove the pen.'*

FDA Label Image

Step 10 (Abrilada 13)

Illustration showing a hand disposing of a used injection pen by placing it into a sharps disposal container. The image is labeled as Step 10 in a sequence, indicating safe disposal instructions for the ABRILADA injection pen by Pfizer Laboratories.*

FDA Label Image

Step 11 (Abrilada 14)

An instructional illustration labeled Step 11 showing a hand holding a cotton ball or gauze pad, wiping the injection site after an injection. This image is part of a sequence demonstrating post-injection care.*

FDA Label Image

Image (Abrilada 15)

Illustrative diagram showing two injection site techniques. The left panel displays the stretch method, indicating to stretch the abdominal skin horizontally with two fingers. The right panel demonstrates the pinch method, where the skin is pinched vertically with thumb and forefinger. The sketches focus on the abdominal area, highlighting finger placement and direction with red arrows.*

FDA Label Image

Pfizer (Abrilada 16)

FDA Label Image

Image (Abrilada 17)

An illustration diagram of a prefilled syringe labeled ABRILADA from Pfizer Laboratories Div Pfizer Inc. The diagram identifies parts of the syringe including the plunger rod, barrel, window displaying expiration date, and needle cover.*

FDA Label Image

Step 3 (Abrilada 18)

Instructional diagram showing Step 3 of unpacking a prefilled syringe for ABRILADA. The image depicts a hand removing the syringe from its packaging tray with a red arrow indicating the direction of removal.*

FDA Label Image

Step 4 (Abrilada 19)

An instructional illustration showing a hand holding a medication device, with a focus on checking the medicine and expiration date as Step 4 in the usage process. The image emphasizes verifying the label date on the medication container.*

FDA Label Image

Step 5 (Abrilada 20)

An instructional diagram showing injection site preparation for ABRILADA. It highlights two recommended injection areas on a simplified human torso: the abdomen (at least 2 inches or 5 cm away from the belly button) and the front upper thigh.*

FDA Label Image

Step 6 (Abrilada 21)

An instructional illustration labeled Step 6 showing hands removing the needle cover from a syringe. A red arrow indicates the upward direction for removing the cover.*

FDA Label Image

Step 7 (Abrilada 22)

An instructional illustration showing Step 7: Insert the needle at a 45-degree angle into the skin of a finger. The image highlights the needle positioning and hand placement for proper technique.*

FDA Label Image

Step 8 (Abrilada 23)

An instructional illustration labeled Step 8 showing a hand holding a syringe, demonstrating the action to inject medicine with a red arrow indicating the direction of injection.*

FDA Label Image

Step 9 (Abrilada 24)

An instructional illustration labeled 'Step 9 Check your syringe' showing a hand holding a syringe to check the needle and contents. The image focuses on the syringe tip with a visible needle, emphasizing proper inspection before use.*

FDA Label Image

Step 10 (Abrilada 25)

Instructional illustration labeled Step 10 for ABRILADA, showing a hand disposing of a used syringe into a sharps disposal container, demonstrating proper syringe disposal technique.*

FDA Label Image

Step 11 (Abrilada 26)

An instructional illustration labeled 'Step 11 After,' depicting a hand using a cotton ball or pad to gently cleanse an area of skin. The image is likely part of a step-by-step guide related to product application or wound care.*

FDA Label Image

Pfizer (Abrilada 27)

FDA Label Image

Principal Display Panel (0.8 mL Prefilled Pen Label)

Label of ABRILADA (adalimumab-afzb) Injection, 40 mg/0.8 mL, a citrate-free formulation. The label indicates it is a single-dose prefilled pen for subcutaneous injection only. It includes storage instructions to refrigerate at 36°F to 46°F (2°C to 8°C) and not to freeze, and mentions the product is manufactured and distributed by Pfizer Laboratories Division of Pfizer Inc.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Abrilda (adalimumab-afzb) Injection, 40 mg/0.8 mL, citrate-free formulation. The label shows a carton containing two single-dose prefilled pens for subcutaneous injection only. It lists included items such as two prefilled pens, two alcohol preps, one package insert, and one medication guide. The product is labeled for Rx use only and is manufactured by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel (0.8 mL Syringe Label)

Packaging label for ABRILADA (adalimumab-afzb) Injection, 40 mg/0.8 mL, a single-dose product for subcutaneous injection only. Label indicates Rx only and is manufactured by Pfizer Inc., New York, NY. The label includes lot and expiration date fields, NDC 0025-0317-01, and a barcode.*

FDA Label Image

Principal Display Panel (0.8 mL Syringe Tray Label)

Label for Abrilada (adalimumab-afzb) Injection, a single-dose prefilled syringe for subcutaneous injection, citrate-free, 40 mg/0.8 mL. The label states no preservative, Rx only, and includes storage instructions. Manufactured by Pfizer Laboratories Div Pfizer Inc, New York, NY.*

FDA Label Image

Principal Display Panel (Kit Carton)

ABRILADA (adalimumab-afzb) injection carton label with a citrate-free formulation, dosage strength of 40 mg per 0.8 mL. The packaging contains two single-dose prefilled syringes with 28-gauge needles for subcutaneous injection, labeled by Pfizer Laboratories Div Pfizer Inc. The label includes usage instructions, storage conditions, and safety warnings.*

FDA Label Image

Principal Display Panel (0.4 mL Syringe Label)

ABRILADA (adalimumab-afzb) Injection 20 mg/0.4 mL single-dose vial label for subcutaneous injection only. The label includes the NDC 0025-0329-01, manufacturer's information (Pfizer Inc., NY), US license number 2001, and space for lot and expiration dates. It features barcodes and a QR code.*

FDA Label Image

Principal Display Panel (0.4 mL Syringe Tray Label)

Label for Abrilada (adalimumab-afzb) Injection, 20 mg/0.4 mL citrate-free, a single-dose prefilled syringe for subcutaneous injection. Label includes storage instructions, manufacturer Pfizer Inc, and safety warnings such as no preservative and refrigeration requirements. Contains a barcode and FDA-required lot information area.*

FDA Label Image

Principal Display Panel (Kit Carton)

Carton packaging for Abrilada (adalimumab-afzb) Injection 20 mg/0.4 mL by Pfizer Laboratories Div Pfizer Inc. It contains two single-dose prefilled syringes with 29 gauge needles for subcutaneous injection. The box includes instructions, medication guide, alcohol preps, and package insert. Storage instructions and warnings are also displayed.*

FDA Label Image

Principal Display Panel (0.2 mL Syringe Label)

Label of ABRILADA (adalimumab-afzb) Injection 10 mg/0.2 mL for subcutaneous injection, single-dose, manufactured by Pfizer Inc. The label includes dosing information, NDC code, lot number, expiration date, and a barcode.*

FDA Label Image

Principal Display Panel (0.2 mL Syringe Tray Label)

Label for Abrilada (adalimumab-afzb) injection, a citrate-free prefilled syringe with a strength of 10 mg/0.2 mL. It is intended for subcutaneous injection, single-dose use, and contains no preservatives. The label includes storage instructions and is manufactured by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel (Kit Carton)

Abrilada (adalimumab-afzb) Injection 10 mg/0.2 mL carton label showing two single-dose prefilled syringes with 29 gauge needles for subcutaneous injection. The packaging includes storage instructions, contents list, and Pfizer Laboratories Div Pfizer Inc as the labeler. The carton is marked citrate-free and prescription only.*

FDA Label Image

Principal Display Panel (0.8 mL Vial Label)

Abrilada (adalimumab-afzb) Injection, 40 mg/0.8 mL, single-dose vial label. The label includes storage instructions to keep at 2°C to 8°C and discard unused portions. It is manufactured by Pfizer Inc, New York, NY. The label states it is for subcutaneous injection and is Rx only. Additional details like NDC 0025-0319-01 are present, along with placeholders for lot and expiration date.*

FDA Label Image

Principal Display Panel (0.8 mL Vial Carton)

ABRILADA (adalimumab-afzb) Injection 40 mg/0.8 mL carton label for a single-dose vial. The label states it is for subcutaneous injection only, for institutional use, and contains no preservatives. It provides storage instructions, composition details, and notes that it is distributed and manufactured by Pfizer Laboratories Division, Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.